Navigation Links
The Efficacy Of Newer Stents Questioned

People who undergo a balloon angioplasty to open a clogged artery often receive a stent as well a small, wire-mesh device inserted into the artery// to keep it from closing. The problem with older stents, however, has been that they can trigger an immune response from the cells in the walls of the artery that cause the artery to become occluded.

Stents coated with drugs to stop this process have been touted as the answer to this problem. Researchers after having collected data from 11 studies comparing bare-metal stents with the newer drug-eluting stents say that their results show people who had the drug-eluting stents were significantly less likely than those receiving the bare-metal stents to experience severe cardiac events, 8 percent vs. 16 percent. They were also more likely to avoid an episode of restenosis, or reblocking of the artery, six to 12 months later, a common problem for anyone undergoing balloon angioplasty. Thirty percent of the bare-metal stent patients experienced reblockage compared to just 9 percent of those who got a drug-eluting stent.

The analysis found no difference in mortality rates or subsequent heart attacks in the two groups. However researchers say long term follow-up is needed to fully determine the safety and effectiveness of drug-eluting stents, especially in patients considered at high risk of complications.
'"/>




Page: 1

Related medicine news :

1. Efficacy Of Meningitis C Vaccine
2. The Efficacy Of Allergy Shots Questioned
3. The Efficacy Of Hormone Replacement Therapy Studied
4. Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief
5. Efficacy of fish oil supplements in pregnancy.
6. Efficacy of Omega 3 Fatty Acids Needs Wider Perspective
7. Thailand To Test Efficacy Of Stem Cell Technology
8. Efficacy Of Sports-Formulated Jelly Beans In Warding Off Fatigue To Be Studied
9. Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs
10. New Study Shows Efficacy of AROMASIN on Early Breast Cancer
11. KADIAN Efficacy Not Affected by Alcohol Consumption
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are used to treat ... if one isn’t accessible in certain locations, the risk of death can be ... with this idea," said an inventor from Ridgecrest, Calif. , The MOBILE AUTOMATED ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from ... in Educational Leadership and Administration at St. Thomas University in Miami, Florida, was ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... and more products at customers’ doorstep. According to Smart Mart, customers can now ... stated to offer wearable, and customers can find clothing at discounted prices. Apart ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for Medical ... p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing ... The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: